Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19-Reference-Cited by-同舟云学术

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19

Published:2021-10 Issue: Volume:40 Page:101102
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Razonable Raymund R.^ORCID,Pawlowski Colin,O'Horo John C.,Arndt Lori L.,Arndt Richard^ORCID,Bierle Dennis M.,Borgen Molly Destro,Hanson Sara N.^ORCID,Hedin Michelle C.,Lenehan Patrick,Puranik Arjun,Seville Maria T,Speicher Leigh L.,Tulledge-Scheitel Sidna M.,Venkatakrishnan AJ,Wilker Caroline G.,Badley Andrew D.,Ganesh Ravindra

Funder

Mayo Clinic

Roche

Gilead Sciences

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. An EUA for bamlanivimab-a monoclonal antibody for COVID-19;JAMA,2020

2. An EUA for casirivimab and imdevimab for COVID-19;Med Lett Drugs Ther,2020

3. An EUA for bamlanivimab and etesevimab for COVID-19;Med Lett Drugs Ther,2021